{"answer":{"query":"trulicity","resolved_as":"name","packages":8,"applications":["BLA125469"],"identity":{"application_numbers":["BLA125469"],"marketing_categories":["BLA"],"labelers":[{"text":"ELI LILLY AND COMPANY","untrusted":true}],"dosage_forms":[{"text":"INJECTION, SOLUTION","untrusted":true}],"marketing_start":{"earliest":"2014-11-07","latest":"2020-09-03","packages_with_a_start_date":4}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":8,"negotiated_price_ends":null,"rows":[{"ndc":"00002143301","name":{"text":"TRULICITY","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002143380","name":{"text":"TRULICITY","untrusted":true},"class":"B","nadac_per_unit":487.6453,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002143401","name":{"text":"TRULICITY","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002143480","name":{"text":"TRULICITY","untrusted":true},"class":"B","nadac_per_unit":487.62033,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002223601","name":{"text":"TRULICITY","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002223680","name":{"text":"TRULICITY","untrusted":true},"class":"B","nadac_per_unit":487.56033,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002318201","name":{"text":"TRULICITY","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00002318280","name":{"text":"TRULICITY","untrusted":true},"class":"B","nadac_per_unit":487.41567,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"label_history":{"events_total":21,"non_cmc_events":21,"counts_by_class":{"LABELING":12,"EFFICACY":7,"REMS":2},"cmc_events":0,"recent_non_cmc_events":[{"application":"BLA125469","submission_no":65,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-03-12","documents":[{"type":"Letter","date":"2026-03-16","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125469Orig1s065ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-03-18","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125469s065lbl.pdf","untrusted":true}}],"fact_id":"cef6169192c1aaa5f9bbd588"},{"application":"BLA125469","submission_no":63,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-05-28","documents":[{"type":"Letter","date":"2025-05-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/125469Orig1s063ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-06-02","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125469s063lbl.pdf","untrusted":true}}],"fact_id":"179bb07491f9b8012bc85eb6"},{"application":"BLA125469","submission_no":62,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-11-01","documents":[{"type":"Label","date":"2024-11-04","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125469s061s062lbl.pdf","untrusted":true}}],"fact_id":"cb2299bb0cfa0dd333af9347"},{"application":"BLA125469","submission_no":61,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-11-01","documents":[{"type":"Label","date":"2024-11-04","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125469s061s062lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-11-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125469Orig1s061, s062ltr.pdf","untrusted":true}}],"fact_id":"d2ab89f446cd4a1e6fbdbb40"},{"application":"BLA125469","submission_no":51,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2022-11-17","documents":[{"type":"Letter","date":"2022-11-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125469Orig1s051ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-11-21","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s051lbl.pdf","untrusted":true}}],"fact_id":"c639207d9cedd2240993338f"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":4,"te_code_counts":{"NOT_PROVIDED":4},"marketing_status_counts":{"Prescription":4},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"BLA125469","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRULICITY","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"0.75MG/0.5ML","untrusted":true}},{"application":"BLA125469","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRULICITY","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"1.5MG/0.5ML","untrusted":true}},{"application":"BLA125469","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRULICITY","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"3MG/0.5ML","untrusted":true}},{"application":"BLA125469","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRULICITY","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"4.5MG/0.5ML","untrusted":true}}]},"recalls":{"recalls_total":3,"counts_by_class":{"Class II":3},"packages_of_these_applications":4,"most_recent":[{"recall_number":"D-0883-2022","classification":"Class II","status":"Completed","report_date":"2022-05-25","recall_initiated":"2022-04-05","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.","untrusted":true},"packages_named":1,"fact_id":"254991ade1ad60be6d8f33b4"},{"recall_number":"D-0884-2022","classification":"Class II","status":"Completed","report_date":"2022-05-25","recall_initiated":"2022-04-05","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions","untrusted":true},"packages_named":4,"fact_id":"ecf0bb9bceb9764e1c87330c"},{"recall_number":"D-0773-2021","classification":"Class II","status":"Terminated","report_date":"2021-09-01","recall_initiated":"2021-08-19","recalling_firm":{"text":"Eli Lilly & Company","untrusted":true},"reason":{"text":"Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.","untrusted":true},"packages_named":4,"fact_id":"eb9c5944eacf14c103140dcf"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"DULAGLUTIDE","untrusted":true},"recruiting_interventional_count":8,"not_yet_recruiting_count":4,"by_phase":{"PHASE3":2,"PHASE2":3,"PHASE4":2,"PHASE2/PHASE3":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT07668336","title":{"text":"A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Eli Lilly and Company","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2026-07-08","link":{"text":"https://clinicaltrials.gov/study/NCT07668336","untrusted":true}},{"nct_id":"NCT05478707","title":{"text":"Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"AdventHealth Translational Research Institute","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-15","start_date":"2023-10-05","link":{"text":"https://clinicaltrials.gov/study/NCT05478707","untrusted":true}},{"nct_id":"NCT06739122","title":{"text":"A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Eli Lilly and Company","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-08-07","start_date":"2025-01-10","link":{"text":"https://clinicaltrials.gov/study/NCT06739122","untrusted":true}},{"nct_id":"NCT04731272","title":{"text":"GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"University of Pennsylvania","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-05-18","start_date":"2021-07-16","link":{"text":"https://clinicaltrials.gov/study/NCT04731272","untrusted":true}},{"nct_id":"NCT06324461","title":{"text":"GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"The University of Hong Kong","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-05-04","start_date":"2024-03-20","link":{"text":"https://clinicaltrials.gov/study/NCT06324461","untrusted":true}}],"fact_id":"97a6b255ab1a6065c9678729"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Lilly Cares Foundation","untrusted":true},"type":"manufacturer","url":"https://www.lillycares.com/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Dulaglutide","untrusted":true},"brand":{"text":"Trulicity","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":3284873061.9,"claims":2823185,"beneficiaries":497327,"average_spending_per_claim_usd":1163.5344697,"fact_id":"80ee49a7fb73067f79ee0277"},{"year":2021,"gross_spending_usd":4702174723.6,"claims":3704201,"beneficiaries":663858,"average_spending_per_claim_usd":1269.4167308,"fact_id":"f27c9e51d313498e291b2a1b"},{"year":2022,"gross_spending_usd":6225291667.6,"claims":4610823,"beneficiaries":840163,"average_spending_per_claim_usd":1350.147613,"fact_id":"422ad3f6b82504be79346ffb"},{"year":2023,"gross_spending_usd":7363856224.3,"claims":5316020,"beneficiaries":938731,"average_spending_per_claim_usd":1385.2198119,"fact_id":"f02012e9878d140175c873dd"},{"year":2024,"gross_spending_usd":5454134725.1,"claims":4305141,"beneficiaries":788716,"average_spending_per_claim_usd":1266.8887558,"fact_id":"ee1a6343c063876bbfb9d9e8"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"biologic_status":{"products":[{"application":"BLA125469","status":"Reference","name":{"text":"Trulicity","untrusted":true},"proper_name":{"text":"dulaglutide","untrusted":true},"license_status":"Licensed","approval_date":"2014-09-18","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":0,"biosimilars":[],"interchangeables":[],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"1df602696b5d286d644db22b"}],"reading":"what the FDA Purple Book lists on its read date, a record and not a forecast of launch or substitution"},"rems":{"programs":[{"application":"BLA125469","program":{"text":"Trulicity","untrusted":true},"rems_id":"322","in_force":false,"released":true,"moved_to_shared_system":false,"has_etasu":false,"program_date":"2014-09-18","last_modified":"2017-12-12","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=322","other_programs":0,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"883fce184af1b0342f59aed8"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"medicaid_state_utilization":{"year":2025,"states_with_data":1,"all_states_medicaid_reimbursed_usd":88786.1,"all_states_medicaid_paid_prescriptions":92,"top_states":[{"state":"WY","medicaid_paid_prescriptions":92,"medicaid_reimbursed_usd":88786.1,"total_reimbursed_usd":88786.1,"packages":1,"covers":"all_record_types","fact_id":"893690b0844f66f7235ee02e"}],"unlabelled_state_code_xx":null,"built_from_facts":1,"facts_fee_for_service_only":0,"older_year_facts_not_used":209,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"eab7f540dd582e041c885cb9","field":"ndc.listing","entity":"ndc:00002143380"},{"fact_id":"1567cb6f174d44e08abda27a","field":"ndc.listing","entity":"ndc:00002143480"},{"fact_id":"e7c586571108fd78875ba658","field":"ndc.listing","entity":"ndc:00002223680"},{"fact_id":"cef6169192c1aaa5f9bbd588","field":"drug.label_event","entity":"application:BLA125469"},{"fact_id":"179bb07491f9b8012bc85eb6","field":"drug.label_event","entity":"application:BLA125469"},{"fact_id":"cb2299bb0cfa0dd333af9347","field":"drug.label_event","entity":"application:BLA125469"},{"fact_id":"d2ab89f446cd4a1e6fbdbb40","field":"drug.label_event","entity":"application:BLA125469"},{"fact_id":"c639207d9cedd2240993338f","field":"drug.label_event","entity":"application:BLA125469"},{"fact_id":"f501cf890fbb3b7cc04ac9b2","field":"drug.marketing_status","entity":"application:BLA125469"},{"fact_id":"b67403ce055adf13988d9151","field":"drug.marketing_status","entity":"application:BLA125469"},{"fact_id":"9cbb7aa833bcea10f590282e","field":"drug.marketing_status","entity":"application:BLA125469"},{"fact_id":"07908a18f4669a94d3cd3e10","field":"drug.marketing_status","entity":"application:BLA125469"},{"fact_id":"254991ade1ad60be6d8f33b4","field":"ndc.recall","entity":"ndc:00002143480"},{"fact_id":"ecf0bb9bceb9764e1c87330c","field":"ndc.recall","entity":"ndc:00002143380"},{"fact_id":"eb9c5944eacf14c103140dcf","field":"ndc.recall","entity":"ndc:00002318280"},{"fact_id":"97a6b255ab1a6065c9678729","field":"drug.trial_access","entity":"drug:dulaglutide"},{"fact_id":"80ee49a7fb73067f79ee0277","field":"drug.partd_spending","entity":"drug:dulaglutide|trulicity"},{"fact_id":"f27c9e51d313498e291b2a1b","field":"drug.partd_spending","entity":"drug:dulaglutide|trulicity"},{"fact_id":"422ad3f6b82504be79346ffb","field":"drug.partd_spending","entity":"drug:dulaglutide|trulicity"},{"fact_id":"f02012e9878d140175c873dd","field":"drug.partd_spending","entity":"drug:dulaglutide|trulicity"},{"fact_id":"ee1a6343c063876bbfb9d9e8","field":"drug.partd_spending","entity":"drug:dulaglutide|trulicity"},{"fact_id":"1df602696b5d286d644db22b","field":"drug.biologic_status","entity":"application:BLA125469"},{"fact_id":"883fce184af1b0342f59aed8","field":"drug.rems","entity":"application:BLA125469"},{"fact_id":"893690b0844f66f7235ee02e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00002318280:WY"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"generic_entry:BLA125469","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry","reason":"no application of this drug has a generic-entry fact; no date is stated"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}